Prognostic importance of thymidylate synthase expression in early breast cancer.
Bernhard C. Pestalozzi(University of Zurich), Patrick G. Johnston(Queen's University Belfast), Monica Castiglione‐Gertsch(University of Geneva), Rastko Golouh(National Institutes of Health), E Simmoncini(National Institutes of Health), Carl‐Magnus Rudenstam(International Breast Cancer Study Group), Harriet F. Peterson(National Institutes of Health), Carmen J. Allegra(National Cancer Institute), Helen Trihia(National Institutes of Health), B A Gusterson(National Institutes of Health), RD Gelber(Harvard University), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), J. Lindtner(National Institutes of Health), H. Cortés-Funes(Centre Hospitalier René-Dubos), Michael Byrne(Breast Cancer Research Foundation)
Cited by 124
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
|UCL Discovery (University College London)|1997|1k